Zidovudine and stavudine sequencing in HIV treatment planning: Findings from the CHORUS HIV cohort

Journal of Acquired Immune Deficiency Syndromes

Volumn 26, Issue 1, 2001, Pages 72-81

  Becker, Stephen L ^a   Raffanti, Stephen R ^b   Hansen, Nellie I ^c   Fusco, Jennifer S ^d   Fusco, Gregory P ^d   Slatko, Gary H ^d   Igboko, Ebere F ^d   Graham, Neil M H ^d  

^a Pacific Horizon Medical Group   (United States)

^b Comprehensive Care Center ^*  (United States)

^c RTI INTERNATIONAL   (United States)

^d GLAXOSMITHKLINE   (United States)

Author keywords

CD4 cell count; HIV 1 RNA; NRTI; Nucleoside reverse transcriptase inhibitor sequencing; Stavudine; Zidovudine

Indexed keywords

RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONGITUDINAL STUDY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; REGRESSION ANALYSIS; SEQUENCE ANALYSIS; STATISTICAL ANALYSIS; TREATMENT FAILURE; TREATMENT OUTCOME; VIRUS LOAD;

EID: 0035144539     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200101010-00011     Document Type: Article

References (37)

1. Antiretroviral therapy in Adults Updated recommendations of the International AIDS Society - USA Panel
2. + T cell responses associated with control of viremia
3. + T-lymphocyte responses after gancyclovir and highly active antiretroviral therapy in individuals infected with HIV-1
4. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic
5. U.S. Centers for Disease Control and Prevention: Report of the NIH panel to define principles of therapy of HIV infection and guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents
6. Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up
7. Efficacy and tolerability of stavudine plus lamivudine in treatment-naive and treatment-experienced patients with HIV-1 infection
8. Anti-HIV antiviral activity of stavudine in a thymidine kinase-deficient cellular line
9. + lymphocytes as prognostic markers of HIV-1 infection
10. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter
11. Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter
12. Delta: A randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals
13. Stavudine in zidovudine (ZDV)-experienced compared with ZDV-naive patients
14. Zidovudine phosphorylation after short-term and log-term therapy with zidovudine in patients infected with the human immunodeficiency virus
15. The effect of zidovudine dose on the formation of intracellular phosphorylated metabolites
16. Metabolism and activities of 3′-azido-2′,3′-dideoxythymidine and 2′-3′-didehydro-2′,3′-dideoxythymidine in herpesvirus thymidine kinase transduced T-lymphocytes
17. Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from AIDS patients after prolonged adefovir dipivoxil therapy
18. Development of zidovudine resistance mutations in patients receiving prolonged didanosine monotherapy
19. Human immunodeficiency virus type 1 reverse transcriptase genotype and drug susceptibility changes in infected individuals receiving dideoxyinosine monotherapy for 1 to 2 years
20. Genotypic and phenotypic analysis of human immunodeficiency virus type 1 isolates from patients on prolonged stavudine therapy
21. Use of viral resistance patterns to antiretroviral drugs in optimising selection of drug combinations and sequences
22. Isolation of drug-resistor variants of HIV-1 from patients on long-term zidovudine therapy
23. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy
24. Susceptibilities of zidovudine-susceptible and -resistant human immunodeficiency virus isolates to antiviral agents determined by using a quantitative plaque reduction assay
25. Biolgical comparison of wild-type and zidovudine-resistant isolates of human immunodeficiency virus type 1 from the same subjects: Susceptibility and resistance to other drugs
26. Study of human immunodeficiency virus resistance to 2′-3′-dideoxyinosine and zidovudine in sequential isolates from pediatric patients on long-term therapy
27. HIV-1 viral load, phenotype, and resistance in a subset of drug-naive participants from the Delta trial
28. Detection of low HIV-1 RNA levels in plasma